1 / 1

Zongertinib(Hernexeos)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Boehringer-Ingelheim

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Hernexeos(Zongertinib) Instructions:Uses,Dosage, Side Effects

HERNEXEOS is a targeted therapy belonging to the kinase inhibitor class. Its active pharmaceutical ingredient is zongertinib. It is formulated as a 60 mg, yellow, film-coated tablet for oral administration, marked with "L6".

The medication is developed and distributed by Boehringer Ingelheim Pharmaceuticals, Inc., under license from Boehringer Ingelheim International GmbH.

Generic name

Zongertinib(Hernexeos)

English name

Zongertinib

Alternative Names

Hernexeos

Drug prices

Indications

HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This approval is under accelerated approval based on objective response rate and duration of response.

Therapeutic Target

Human Epidermal Growth Factor Receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations.

Active Ingredients

Zongertinib

Dosage form

TABLET

specifications

60mg * 60 tablets/box

Description

Dosage and Administration

Administered orally once daily, with or without food. The dose is based on body weight: 120 mg for patients weighing less than 90 kg and 180 mg for patients weighing 90 kg or more. Treatment continues until disease progression or unacceptable toxicity.

CATEGORY NAVIGATION

RECOMMENDED ARTICLES

How to Purchase Zongertinib

Zongertinib is a targeted therapeutic agent for non-small cell lung cancer (NSCLC) harboring activating mutations in...

Saturday, October 11th, 2025, 15:03

Indication of Zongertinib

Zongertinib is a novel kinase inhibitor recently granted accelerated approval by the U.S. FDA. As a targeted therapy...

Saturday, October 11th, 2025, 14:58

How to Use Zongertinib

Zongertinib is a novel kinase inhibitor indicated for the treatment of adult patients with unresectable or...

Saturday, October 11th, 2025, 14:34

Precautions for Zongertinib Administration

Zongertinib is a kinase inhibitor that targets activating mutations in the tyrosine kinase domain of HER2 (ERBB2)....

Saturday, October 11th, 2025, 14:31

What Are the Side Effects of Zongertinib?

Zongertinib is a kinase inhibitor targeting activating mutations in the tyrosine kinase domain of HER2 (ERBB2). It...

Saturday, October 11th, 2025, 14:24

What Are the Side Effects of Zongertinib?

Zongertinib is a kinase inhibitor that targets activating mutations in the tyrosine kinase domain of HER2 (ERBB2)....

Sunday, September 28th, 2025, 16:38

Departments

Oncology Hematology Immunology Hepatology Endocrinology Pulmonology Neurology Cardiology Gastroenterology Dermatology

Contact Medical Consultant

Global Drug Search

Clinical recruitment

overseas medical treatment

Remote consultation

Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.

Click to submit medical consultant

Mailbox:Info@Lucius.La

Welcome To Consult